Versantis closes a CHF 16M Series B financinground to advance clinical development of VS-01 up to Phase 2a in 2 indications !
Versantis initiated the first clinical trial of its lead candidate VS-01 for cirrhotic patients with hepatic encephalopathy.
Handelszeitung reports about Versantis' promising novel technology for liver diseases.
Einblick magazine features Versantis as a life-saving innovative company!
For the 5th year in a raw, Versantis ranks among Top100 best Swiss startups and was elected #2 BEST BIOTECH !
Versantis wins MassChallenge Switzerland!!
HOMEABOUT USDISEASE AREASPRODUCTSNEWSCAREERS
Versantis AGTechnoparkstrasse 13rd floor, Newton wing 3007CH-8005 ZurichSwitzerland
Copyright © 2019Versantis AG